Full Press Release Details
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months ended September 30, 2017, and provide important corporate updates, on Tuesday, October 17.
Tuesday, October 17, 2017 @ 8:30am Eastern Time
| Toll Free: | 888-395-3237 |
| Israel Investors: | 1 80 924 5905 |
| International: | 719-325-2349 |
| Conference ID: | 4131959 |
| Webcast: | http://public.viavid.com/index.php?id=126580 |
Replays, available through October 31, 2017
| Toll Free: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 4131959 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Chief Business Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
LifeSci Advisors, LLC
SOURCE BrainStorm Cell Therapeutics Inc.
Related Links
21 %
more press release views with